We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+18.46%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$151M
AUM Growth
-$29.7M
Cap. Flow
+$9.23M
Cap. Flow %
6.1%
Top 10 Hldgs %
42.62%
Holding
71
New
15
Increased
21
Reduced
14
Closed
14
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.7 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$4.74M
2
IBB icon
iShares Biotechnology ETF
IBB
+$3.78M
3
GILD icon
Gilead Sciences
GILD
+$3.06M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.72M
5
MRK icon
Merck
MRK
+$2.59M

Top Sells

Rank Stock Value
1
TECH icon
Bio-Techne
TECH
+$4.35M
2
CPHD
Cepheid Inc
CPHD
+$4.07M
3
AZN icon
AstraZeneca
AZN
+$2.85M
4
BIIB icon
Biogen
BIIB
+$2.01M
5
MTD icon
Mettler-Toledo International
MTD
+$1.76M

Sector Composition

Rank Sector Weight
1 Healthcare 85.26%
2 Miscellaneous 14.74%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CLVS
26
DELISTED
Clovis Oncology, Inc.
CLVS
$1.75M 1.16%
50,000
-8,567
-15% -$552K
2014 Q4
4 quarters
LOXO
27
DELISTED
Loxo Oncology, Inc
LOXO
$1.71M 1.13%
+60,000
New +$1.61M
2015 Q4
0 quarters
AZN icon
28
AstraZeneca
AZN
$259B
$1.67M 1.1%
24,550
-43,450
-64% -$2.85M
2015 Q2
2 quarters
NSTG
29
DELISTED
NanoString Technologies, Inc.
NSTG
$1.5M 0.99%
102,200
– –
2015 Q2
2 quarters
PCRX icon
30
Pacira BioSciences
PCRX
$1.45B
$1.47M 0.97%
19,110
-1,890
-9% -$107K
2015 Q1
3 quarters
ZGNX
31
DELISTED
Zogenix, Inc.
ZGNX
$1.41M 0.93%
95,700
+30,000
+46% +$403K
2015 Q1
3 quarters
RXDX
32
DELISTED
Ignyta, Inc.
RXDX
$1.34M 0.89%
+100,000
New +$1.21M
2015 Q4
0 quarters
ISEE
33
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.33M 0.88%
17,000
+9,850
+138% +$570K
2015 Q3
1 quarter
XNCR icon
34
Xencor
XNCR
$1.78B
$1.32M 0.87%
+90,000
New +$1.21M
2015 Q4
0 quarters
DRNA
35
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.19M 0.78%
+100,000
New +$1.14M
2015 Q4
0 quarters
MCRB icon
36
Seres Therapeutics
MCRB
$25.4M
$1.16M 0.77%
+1,650
New +$1.08M
2015 Q4
0 quarters
PRTK
37
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.14M 0.75%
+60,000
New +$1.15M
2015 Q4
0 quarters
ACHN
38
DELISTED
Achillion Pharmaceuticals
ACHN
$1.08M 0.71%
100,000
-6,104
-6% -$55.5K
2014 Q4
4 quarters
BIB icon
39
ProShares Ultra NASDAQ Biotechnology
BIB
$93.3M
$1.07M 0.7%
14,919
-17,798
-54% -$1.19M
2014 Q4
4 quarters
BCRX icon
40
BioCryst Pharmaceuticals
BCRX
$2.05B
$1.03M 0.68%
+100,000
New +$994K
2015 Q4
0 quarters
UTHR icon
41
United Therapeutics
UTHR
$23.2B
$1.02M 0.67%
6,514
+943
+17% +$137K
2014 Q4
4 quarters
MACK icon
42
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$968K 0.64%
15,570
+7,689
+98% +$541K
2014 Q4
4 quarters
MDCO
43
DELISTED
Medicines Co
MDCO
$934K 0.62%
+25,000
New +$945K
2015 Q4
0 quarters
MGNX icon
44
MacroGenics
MGNX
$215M
$929K 0.61%
+30,000
New +$911K
2015 Q4
0 quarters
VCEL icon
45
Vericel Corp
VCEL
$2.1B
$857K 0.57%
332,157
– –
2014 Q4
4 quarters
NVAX icon
46
CALL
Novavax
NVAX
$2.11B
$839K 0.55%
5,000
– –
2015 Q3
1 quarter
NVAX icon
47
PUT
Novavax
NVAX
$2.11B
$839K 0.55%
5,000
– –
2015 Q3
1 quarter
KPTI icon
48
Karyopharm Therapeutics
KPTI
$7.96M
$795K 0.53%
4,000
+3,017
+307% +$653K
2015 Q3
1 quarter
LAB icon
49
Standard BioTools
LAB
$258M
$757K 0.5%
70,000
+55,000
+367% +$540K
2015 Q3
1 quarter
AVDL
50
DELISTED
Avadel Pharmaceuticals
AVDL
$693K 0.46%
56,788
– –
2014 Q4
4 quarters
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2015 Portfolio in Review

As of Q4 2015, Opus Point Partners Management held 71 positions worth $151M, down 16% from $181M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opus Point Partners Management deployed $9.23M of net new capital in Q4 2015, opening 15 new positions and adding to 21 existing holdings. Its largest new stake was Loxo Oncology, Inc: 60,000 shares worth $1.71M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was AstraZeneca, an estimated $2.85M trimmed.

  • Opus Point Partners Management's largest Q4 2015 buy was Loxo Oncology, Inc: 60,000 shares worth $1.71M.
  • Opus Point Partners Management added most to Amgen in Q4 2015, an estimated $4.74M increase.
  • Opus Point Partners Management's biggest Q4 2015 reduction was AstraZeneca, cutting an estimated $2.85M.
  • Opus Point Partners Management fully exited Bio-Techne in Q4 2015, selling an estimated $4.35M.
  • Opus Point Partners Management's ten largest holdings make up 43% of its $151M portfolio in Q4 2015.
  • Opus Point Partners Management opened 15 new positions and closed 14 in Q4 2015.
  • Opus Point Partners Management's portfolio value fell 16% quarter-over-quarter to $151M.

Based on Opus Point Partners Management's 13F filing for Q4 2015, filed 16 Feb 2016.